srx246 srx246 srx246, also known as api-246, is a small-molecule, centrally-active, highly-selective vasopressin v1a receptor antagonist which is under investigation by azevan pharmaceuticals for the treatment of affective and anger disorders. it is an azetidinone derivative, and was developed from ly-307174 as a lead compound. a phase ii activity trial of the drug in the treatment of adults with intermittent explosive disorder is ongoing. it is also being studied for the treatment of post-traumatic stress disorder. srx246clinical dataatc codenoneidentifiers iupac name (r)-4-(-1'-yl)-4-oxo-2-((3s,4r)-2-oxo-3-((s)-2-oxo-4-phenyloxazolidin-3-yl)-4-((e)-styryl)azetidin-1-yl)-n-((r)-1-phenylethyl)butanamide cas number512784-93-9chemspider23290398unii372x2p22uychemical and physical dataformulac42h49n5o5molar mass703.884 g·mol−13d model (jsmol)interactive image smiles o=c1(n2c(oc2c3=cc=cc=c3)=o)(/c=c/c4=cc=cc=c4)n1(c(n(c)c5=cc=cc=c5)=o)cc(n6ccc(n7ccccc7)cc6)=o inchi inchi=1s/c42h49n5o5/c1-30(32-16-8-3-9-17-32)43-40(49)36(28-38(48)45-26-22-34(23-27-45)44-24-12-5-13-25-44)46-35(21-20-31-14-6-2-7-15-31)39(41(46)50)47-37(29-52-42(47)51)33-18-10-4-11-19-33/h2-4,6-11,14-21,30,34-37,39h,5,12-13,22-29h2,1h3,(h,43,49)/b21-20+/t30-,35-,36-,37-,39+/m1/s1key:fjukoxwsigulle-jvoqcoeysa-n